Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -120.33% is 138% below its 5-year average of -50.64%, around the middle of its 5-year range (-242.45%–-18.99%).
As of the fiscal period ended Tuesday, June 30, 2026. 24.63% above its 12-month average of -159.65%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -120.33%.
RETURN ON EQUITY (ROE)
-120.33%
RETURN ON EQUITY (ROE) AVG TTM
-159.65%
RETURN ON EQUITY (ROE) AVG 3Y
-78.21%
RETURN ON EQUITY (ROE) AVG 5Y
-50.64%
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
+24.63%
CURRENT VS 3Y AVG
-53.86%
CURRENT VS 5Y AVG
-137.61%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-41.78%
median of 742 covered companies
CURRENT VS SECTOR MEDIAN
-187.96%
vs the sector median at left
Nyxoah S.A.
Market Cap
$143.10M
Return on Equity (ROE)
-120.33%
TTM Avg
-159.65%
3Y Avg
-78.21%
5Y Avg
-50.64%
Market Cap
$142.76M
Return on Equity (ROE)
-43.40%
TTM Avg
-27.96%
3Y Avg
-44.92%
5Y Avg
-37.65%
Market Cap
$141.00M
Return on Equity (ROE)
N/A
TTM Avg
-182.86%
3Y Avg
-123.00%
5Y Avg
-90.58%
Market Cap
$140.52M
Return on Equity (ROE)
68.12%
TTM Avg
-94.32%
3Y Avg
-166.28%
5Y Avg
-128.51%
Market Cap
$140.31M
Return on Equity (ROE)
-30.03%
TTM Avg
-86.56%
3Y Avg
-69.53%
5Y Avg
-37.30%
Market Cap
$146.26M
Return on Equity (ROE)
-183.44%
TTM Avg
-114.28%
3Y Avg
-67.72%
5Y Avg
-46.03%
Market Cap
$146.76M
Return on Equity (ROE)
-131.85%
TTM Avg
-36.69%
3Y Avg
-135.43%
5Y Avg
-129.92%
Market Cap
$138.93M
Return on Equity (ROE)
-44.26%
TTM Avg
-34.18%
3Y Avg
285.39%
5Y Avg
-5868.11%
Market Cap
$147.73M
Return on Equity (ROE)
-69.78%
TTM Avg
-41.37%
3Y Avg
-26.34%
5Y Avg
-26.08%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Nyxoah S.A. (NYXH) | $143.10M | -120.33% | -159.65% | -78.21% | -50.64% |
| Protara Therapeutics, Inc. (TARA)vs › | $142.76M | -43.40% | -27.96% | -44.92% | -37.65% |
| Sutro Biopharma, Inc. (STRO)vs › | $141.00M | N/A | -182.86% | -123.00% | -90.58% |
| Fortress Biotech, Inc. (FBIOP)vs › | $140.52M | 68.12% | -94.32% | -166.28% | -128.51% |
| Immuneering Corporation (IMRX)vs › | $140.31M | -30.03% | -86.56% | -69.53% | -37.30% |
| Acumen Pharmaceuticals, Inc. (ABOS)vs › | $146.26M | -183.44% | -114.28% | -67.72% | -46.03% |
| Korsana Biosciences, Inc. (KRSA)vs › | $146.76M | -131.85% | -36.69% | -135.43% | -129.92% |
| Alpha Cognition Inc (ACOG)vs › | $138.93M | -44.26% | -34.18% | 285.39% | -5868.11% |
| Voyager Therapeutics, Inc. (VYGR)vs › | $147.73M | -69.78% | -41.37% | -26.34% | -26.08% |
| Anavex Life Sciences Corp. (AVXL)vs › | $148.27M | -21.38% | -42.33% | -37.95% | -45.57% |
ROE
-120.3%
ROA
-59.4%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -120.33% |
| 2026-03-31 | -242.45% |
| 2025-12-31 | -179.85% |
| 2025-09-30 | -157.09% |
| 2025-06-30 | -98.54% |
| 2025-03-31 | -74.71% |
| 2024-12-31 | -54.28% |
| 2024-09-30 | -49.68% |
| 2024-06-30 | -36.48% |
| 2024-03-31 | -49.83% |
| 2023-12-31 | -43.35% |
| 2023-09-30 | -40.14% |
| 2023-06-30 | -34.21% |
| 2023-03-31 | -26.17% |
| 2022-12-31 | -25.62% |
| 2022-09-30 | -20.24% |
| 2022-06-30 | -20.63% |
| 2022-03-31 | -20.84% |
| 2021-12-31 | -18.99% |
| 2021-06-30 | -20.37% |
| 2021-03-31 | -14.22% |
| 2020-12-31 | -11.72% |
| 2020-09-30 | -10.36% |
| 2020-06-30 | -34.36% |
| 2020-03-31 | -386.25% |
| 2019-12-31 | -356.01% |
